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Malignant gliomas are the most aggressive forms
of brain tumors, associated with high rates of
morbidity and mortality. Recurrence and tumorigen-
esis are attributed to a subpopulation of tumor-initi-
ating glioma stem cells (GSCs) that are intrinsically
resistant to therapy. Initiation and progression of
gliomas have been linked to alterations in microRNA
expression. Here, we report the identification of
microRNA-138 (miR-138) as a molecular signature
of GSCs and demonstrate a vital role for miR-138
in promoting growth and survival of bona fide
tumor-initiating cells with self-renewal potential.
Sequence-specific functional inhibition of miR-138
prevents tumorsphere formation in vitro and
impedes tumorigenesis in vivo. We delineate the
components of the miR-138 regulatory network by
loss-of-function analysis to identify specific regula-
tors of apoptosis. Finally, the higher expression of
miR-138 in GSCs compared to non-neoplastic tissue
and association with tumor recurrence and survival
highlights the clinical significance of miR-138 as
a prognostic biomarker and a therapeutic target for
treatment of malignant gliomas.INTRODUCTION
Malignant gliomas are comprised of anaplastic astrocytoma
(WHO grade III) and glioblastoma multiforme (GBM) (WHO
grade IV) lesions that are highly invasive and display histological
evidence of malignancy. Patients with such highly aggressive,
often lethal intracranial malignancy have a median survival of
less than 12 months (Legler et al., 1999). Composed of a hetero-
geneous mixture of poorly differentiated neoplastic astrocytes,
malignant gliomas primarily affect adults and preferentially occurCelin the cerebral hemispheres. Despite the current multimodality of
treatment strategies (Garden et al., 1991), frequent recurrence of
the tumors has been attributed to intrinsically resistant glioma
stem cells (GSCs) critical for gliomagenesis (Bao et al., 2006a;
Galli et al., 2004; Hemmati et al., 2003; Singh et al., 2004).
They are chemo- and radio-resistant and, therefore, responsible
for tumor progression and recurrence (Bao et al., 2006a). The
infiltrative nature of GSCs coupled with their resistance to
standard therapy has restricted the development of successful
treatment.
The molecular mechanisms that contribute to gliomagenesis
are poorly understood. Alterations in the expression of endoge-
nous small noncoding RNAs, themicroRNAs (miRNAs), may play
a crucial role in cancer initiation, progression, and metastasis
(Calin and Croce, 2006; Ma et al., 2007). miRNAs can function
as tumor suppressors or oncogenes by binding to complemen-
tary sequences on the respective target mRNA (Esquela-
Kerscher and Slack, 2006; Slack and Weidhaas, 2006). The
reduced/loss of expression of a miRNA may lead to aberrant
expression of its target proteins, resulting in an altered pheno-
type. Impaired miRNA regulatory network is known to be one
of the key mechanisms in brain tumor pathogenesis (Bottoni
et al., 2005; Chan et al., 2005). Comparison of the miRNA
profiles of glial tumors, embryonic stem cells (ESCs), neural
precursor cells (NPCs), and normal adult brain tissues has
revealed that primary gliomas have NPC-like miRNA ex-
pression (Lavon et al., 2010). Specific role of miRNA-21 (miR-
21), miR-451, and miR-9/9* in GBM suggests that they are
potential targets for therapeutic intervention (Chan et al., 2005;
Corsten et al., 2007; Godlewski et al., 2010; Schraivogel et al.,
2011). Overexpression of miR-34a, miR-137, and miR-451
inhibits proliferation, disrupts neurosphere formation, or in-
duces differentiation of GSCs, respectively, but does not lead
to apoptotic death of GSCs (Gal et al., 2008; Guessous et al.,
2010; Li et al., 2009; Silber et al., 2008). In this study we
demonstrate the role of miR-138 as a prosurvival oncomiR
for GSCs and a regulator of GSC growth and survival. We further
demonstrate the association of miR-138 with tumor recurrence
and survival.l Reports 2, 591–602, September 27, 2012 ª2012 The Authors 591
Figure 1. GSCs Display a Unique miRNA
Signature
(A) Graphic representation of differential miRNA
expression. The scatterplot represents the tran-
script abundance of miRNAs in GSCs versus
NSCs. The vertical axis shows the transcript
abundance in NSCs, whereas the horizontal axis
shows the transcript abundance in GSCs.
(B) miR-138 expression analysis in NSCs and
GSCs by quantitative stem-loop real-time reverse-
transcription PCR Three NSC lines are repre-
sented as SVZ, FL, Lon (Lonza), and five GSC lines
as NNI-1, NNI-4, NNI-8, NNI-11, and NNI-12.
(C) Expression of miR-138 in NSCs and GSCs
validated by northern blot analysis.
(D) Expression of pre-miR-138-1 and pre-miR-
138-2 in NSCs and GSCs.
(E) miR-138 expression analysis by quantitative
stem-loop real-time reverse-transcription PCR in
GSCs on differentiation.
N.S., not significant; **p < 0.001.
See also Figure S1.RESULTS
GSCs Display a Unique miRNA Signature
GSCs derived from five patients with malignant glioma, NNI-1,
NNI-4, NNI-8, NNI-11, and NNI-12 (Ng et al., 2012), were first
characterized for their self-renewal, multipotency, and tumori-
genic properties. Similar to the normal human neural stem cells
(NSCs), all GSC lines form spheres in culture and express
markers like CD133 (Prominin-1) and Nestin (Figures S1A and
S1B). GSCs not only self-renew as confirmed by single-cell592 Cell Reports 2, 591–602, September 27, 2012 ª2012 The Authors(clonal) sphere-formation assays (Rey-
nolds and Rietze, 2005), they also un-
dergo multipotent differentiation (Figures
S1C and S1D). However, unlike NSCs,
GSCs are tumorigenic. Tumor mass
could be observed 4–6 months after
intracranial transplantation of GSCs in
NOD-SCID mice (Figure S1E) (Bao et al.,
2006b; Galli et al., 2004), confirming the
tumorigenic potential of GSCs.
To address the tumorigenic properties
of GSCs, we compared the miRNA
expression profiles of GSCs with NSCs.
Using ANOVA on normalized ChIP data,
we identified differentially expressed
miRNAs. The overall miRNA expression
pattern in NSCs is very similar to that of
GSCs, as revealed by scatterplot of
miRNA expression profile. Among the
few differentially expressed transcripts,
miR-138 emerged as the most significant
differentially expressed miRNA (Fig-
ure 1A). Expression of miR-138 was
validated by quantitative stem-loop real-
time reverse-transcription PCR (Fig-
ure 1B). These results were confirmedby northern blot analysis using specific LNA probes that recog-
nize miR-138 (Figure 1C). Because miR-138 has two putative
precursors, pre-miR-138-1 and pre-miR-138-2, and the syn-
thesis of maturemiR-138 is regulated by stringent transcriptional
and posttranscriptional control mechanisms (Obernosterer et al.,
2006), we analyzed the expression of precursor transcripts in
GSCs and NSCs. The detection of elevated levels of pre-miR-
138-2 only in GSCs, not in NSCs, suggests that miR-138 is under
tight transcriptional control in NSCs (Figure 1D). Next, we
analyzed the expression of miR-138 when GSCs were subjected
Figure 2. Targeting miR-138 in GSCs Impedes Formation of Tumorspheres
(A) Representative images of tumorspheres fromGSCs transduced with scramble control (top panel) and antimiR-138 (bottom panel). Note a significant reduction
in tumorsphere formation by day (D) 9 in GSCs transduced with antimiR-138 relative to the scramble control.
(B) The histogram represents average diameter of tumorspheres at indicated time points in GSCs transducedwith antimiR-138 or scramble control. The error bars
are the relative mean ± SD of 30 spheres.
(C) The line graph indicates that the number of viable cells increased with time in GSCs transduced with scramble control, but not in GSCs transduced with
antimiR-138.
(D) Formation of tumorspheres is hampered by the loss of miR-138. Of the wells that were confirmed to contain one viable cell, 26% ± 1.5% (n = 3 independent
cultures) formed tumorspheres in scramble control, whereas targeting miR-138 in GSCs prevented tumorsphere formation. A clone-derived tumorsphere
(representative image below) can be observed only in scramble control, not in GSCs transduced with antimiR-138.
(E) Expression levels of miR-138, miR-106a, miR-21, miR-886, and miR-1274a in GSCs transduced with scramble control or antimiR-138.
(F) Representative neurosphere images of NSCs transduced with scramble control (top panel) and antimiR-138 (bottom panel).
Scale bars, 100 mm. **p < 0.001.
See also Figure S2.to differentiation. Clearly, transcript levels of miR-138 were
significantly downregulated when GSCs differentiated (Fig-
ure 1E). Together, these results indicate that GSCs consistently
and reliably express elevated levels of miR-138 relative to NSCs.
Functional Characterization of miR-138
To understand the functional significance of elevated expression
levels of miR-138 in GSCs, we used lentiviral-based antagomirs
to obtain stable loss-of-function phenotype (Kru¨tzfeldt et al.,
2005; Scherr et al., 2007). To control for potential off-target
effects, a nontargeting-scrambled (scramble) control was
used. Lentivirus-transduced cells were subjected to puromycin
selection. Sequence-specific inhibition of miRNA-138 by lenti-
virus encoded antagomiR-138 (antimiR-138), affected growth
and survival of GSCs (Figure 2A), and this is apparent by
a decrease in size of tumorspheres compared to the scramble
control (Figure 2B). To confirm that the effect observed was
not due to differences in lentivirus transduction or integrationCelefficiency, transduction efficiency was assayed by FACS and
qPCR quantification of LTRGAG and GFP (vector-derived
sequences) (Figures S2A and S2B).
Cell titer-growth curve assay demonstrated that the total
number of viable scramble control GSCs increased by 10-fold
over 7 days, whereas GSCs depleted of miR-138 decreased in
number, indicating thatmiR-138 preferentially contributes to sus-
tained growth of GSCs (Figure 2C). Clonogenic assays on GSCs
transduced either with antimiR-138 or scramble control
confirmed the same, where in 26% ± 1.5% (n = 3 independent
culture preparations) of wells formed tumorspheres in scramble
control, whereas targeting miR-138 in GSCs prevented tumor-
sphere formation (Figure 2D). Supporting this observation, when
single-cell suspension of GSCs transduced with antimiR-138 or
scramble control was plated in soft agar, macroscopically visible
colonies were observed only in GSCs transduced with scramble
control, but not with antimiR-138 (Figure S2C). Collectively, these
results suggest that miR-138 is essential for the growth andl Reports 2, 591–602, September 27, 2012 ª2012 The Authors 593
Figure 3. miR-138 Is a Prosurvival OncomiR for GSCs
(A) Cell-cycle analysis indicates a decrease in percentage of cells in S phase, coupled with an increase in the percentage of cells in the sub-G1 phase in antimiR-
138-transduced GSCs.
(B) Immunoblot analysis for phosphoprotein histone 3 and cleaved PARP.
(C) Caspase-3/7 activity relative to the cell number increased in antimiR-138 transduced GSCs relative to the scramble control.
(D) Annexin V staining demonstrates increased apoptosis in GSCs transduced with antimiR-138 compared to the scramble control.
(E) TUNEL staining exhibits elevated apoptosis in antimiR-138-transduced GSCs relative to the scramble control. Scale bars, 50 mm.
**p < 0.001.survival of bona fide stem cells with self-renewal potential. A
significant decrease in the level of only miR-138, and no change
in the levels of miR-886, miR-106, miR-21, and miR-1274a in
GSCs transduced with antimiR-138 relative to the scramble
control, confirms that antimiR-138 is highly transcript specific
(Figure 2E). Neurosphere-formation capacity of NSCs was not
affected when transduced with either antimiR-138 or scramble
control, indicating cell specificity of antimiR-138 and highlights
that antimiR-138 has no toxic effect on normal cells (Figure 2F).594 Cell Reports 2, 591–602, September 27, 2012 ª2012 The AuthorTargeting miR-138 Inhibits Proliferation and Promotes
Apoptosis of GSCs
To determine the specific role of miR-138 in regulating prolifera-
tion and growth, a dual-color flow cytometric analysis with DNA
content determination was performed on GSCs transduced with
scramble control or antimiR-138. A reduction in cellular entry into
S phase (Figure 3A), coupled with reduced expression of phos-
phohistone H3 (Figure 3B), a proliferation marker of cells in late
G2 and M phase, in GSCs transduced with antimiR-138 but nots
Figure 4. miR-138 Is an Essential Prosur-
vival OncomiR for GSCs
(A) Representative real-time images of xenografts
tracked by bioluminescence at indicated time
points after engraftment. Bioluminescence de-
tected on days 2 and 6 in antimiR-138-bearing
GSCs and scramble control-bearing GSCs, indi-
cating survival of transplanted cells (n = 10).
(B) Representative light micrograph showing H&E
for GSC-derived tumor showing characteristic
intracranial tumor location in immunocompro-
mised mice. Tumor mass detected only in mice
bearing nontargeting scramble-expressing GSCs.
(C) Survival plot indicates development of intra-
cranial tumors and neurological symptoms only in
mice implanted with GSCs expressing scrambled
control.
(D) ISH on xenograft tumor sections or control
normal tissue section probed with miR-138 probe
or scramble probe. Scale bar, 100 mm.
(E) ISH on xenograft tumor sections to detect miR-
138 expression along with coimmunostaining for
CD133 (right panel). Higher magnification of the
same (left panel). Note that all CD133-positive
GSCs do not express miR-138 (white arrowhead);
only a subpopulation of CD133-positive GSCs
expresses miR-138 (red arrowhead). The box
represents the region magnified in the next panel.
Scale bar, 20 mm.scramble control indicates attenuation of proliferation. A robust
increase in sub-G1 population (Figure 3A), accompanied by
detection of 89 kDa poly-ADP-ribose polymerase (PARP)
cleavage fraction in GSCs transduced with antimiR-138, but
not with scramble control, suggests that knockdown of miR-
138 leads to apoptosis (Figure 3B). Functional inhibition of
miR-138 prevents tumorsphere formation partly due to attenua-
tion of proliferation, coupled with apoptotic cell death of GSCs.
Supporting this result, Caspase-3/7 activity normalized to cell
number increased in miR-138-targeted GSCs compared to the
scramble control (Figure 3C). Further targeting miR-138 in
GSCs increased the percentage of annexin V-positive cellsCell Reports 2, 591–602, Sewhen compared to the scramble control,
suggesting increased apoptosis (Fig-
ure 3D). Finally, increased terminal deox-
ynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining that detects
DNA fragments in late phase of
apoptosis, only in antimiR-138 targeted
GSCs, not with scramble control (Fig-
ure 3E), suggests that targeting miR-138
results in increased apoptotic death of
GSCs, highlighting that miR-138 is a pro-
survival oncomiR for GSCs.
miR-138 Is an Essential Prosurvival
OncomiR for GSCs
To evaluate the role of miR-138 expres-
sion in GSCs and tumorigenicity, we
intracranially implanted luciferase-ex-pressing GSCs bearing antimiR-138 or nontargeting scramble
into the forebrains of immunocompromised mice (n = 10). The
viability of the engrafted GSCs was measured by tracking the
bioluminescence after implantation (Figure 4A). The biolumines-
cence measured on days 2 and 6 after implantation indicates
that the antimiR-138-expressing GSCs survive transplantation
like the scramble control. However, tumorigenesis only in mice
bearing GSCs expressing scramble control not in mice bearing
GSCs expressing antimiR-138 suggests that functional inhibition
of miR-138 leads to apoptotic death of GSCs and impedes
tumorigenesis (Figures 4B and 4C). The xenograft tumor
sections, but not the control normal brain sections, exhibitedptember 27, 2012 ª2012 The Authors 595
Figure 5. miR-138 Impedes Apoptosis and Promotes Proliferation
(A) Expression values of selected genes frommicroarray data represented as a heatmap, displayed in shades of red or blue relative to the individual mean value of
the gene in a linear scale.
(B) Scatterplot represents the fold changes (Scramble/AntimiR-138) of selected genes obtained from microarray and quantitative stem-loop real-time reverse-
transcription PCR (qRT-PCR). A trend line was plotted by linear regression using the least-squares method and R2 = 0.96.
(C) Immunoblot analysis of selected genes in GSCs transduced with antimiR-138 or scramble control.
(D) Validation of direct targets of miR-138 by reporter assays. Cells cotransfected with indicated 30 UTR luciferase reporter constructs either with miR-138 or
control vector. Normalized relative luciferase activity is shown as a bar diagram. Luciferase activity is expressed as mean relative to controls ±SD (**p < 0.001).
See also Figure S3.positive staining for miR-138 as observed by in situ hybridization
(ISH) (Figure 4D). GSCs expressingmiR-138 also express CD133
(Figure 4E); however, not all CD133-positive cells express miR-
138, suggesting that a subpopulation of CD133-positive cells
is tumor-initiating GSCs. Taken together, miR-138 activity in
GSCs relates primarily to the maintenance and survival of
GSCs, and miR-138-positive GSCs are tumorigenic.
miR-138 Targets Tumor Suppressors and Proapoptotic
Genes
Furthermore, to delineate the underlying mechanism of miR-138
as a prosurvival oncomiR, we sought to identify the targets by
comparing gene expression profiles from GSCs transduced
with either antimiR-138 or scramble control. Representation of
selected array data as a heatmap displayedmultiple differentially596 Cell Reports 2, 591–602, September 27, 2012 ª2012 The Authorexpressed genes (Figure 5A). A linear correlation between array
and quantitative stem-loop real-time reverse-transcription PCR
indicates that the array profiles can be used to ascertain global
and specific properties of miR-138 (Figure 5B). Several of the
candidate gene products were analyzed by immunoblotting,
and expected changes in protein levels were observed.
Increased expression of specific genes on functional inhibition
of miR-138 suggests that these genes are potential targets of
miR-138 (Figure 5C).
Interrogation of TargetScan v5.1 database and correlation
of the predicted targets with microarray data revealed potential
direct targets of miR-138. These include Caspase-3 (CASP3),
Bladder cap-associated protein (BLCAP), and MAX dimerization
protein 1 (MXD1), each with at least one conserved binding
site for miR-138. To determine the ability of miR-138 tos
Figure 6. miR-138 PromotesGliomagenesis
(A) Model depicting miR-138 network. As a nega-
tive regulator, miR-138 targets proapoptotic
genes and blocks apoptosis. As a positive regu-
lator, miR-138 targets tumor suppressors, tran-
scriptional repressors, and indirectly facilitates
expression genes that promote survival and
proliferation of GSCs.
(B) Log-log plot of the normalized expression
levels of miR-138 versus miR-21 from samples
derived from patients with secondary and primary
GBM. Expression levels of the miRNAs were
normalized against normal non-neoplastic brain
tissue. Data were obtained from GEO database
(accession number GSE13030).negatively regulate CASP3, MXD1, and BLCAP expression,
chimeric 30 UTR luciferase reporter assays were performed.
Expression of miR-138 resulted in significant downregulation of
reporter activity withCASP3,MXD1, orBLCAPwild-type 30 UTR,
whereas the reporter vector with a mutation in miR-138
binding site was not affected, confirming that CASP3, MXD1,
andBLCAP are direct targets ofmiR-138 (Figure 5D). Repressing
CASP3, a proapoptotic gene, and BLCAP, a tumor suppressor,
miR-138 prevents apoptosis and S phase arrest. Targeting
MXD1 (MAD), a transcriptional repressor that competes with
MYC for binding to MAX (Amati et al., 1993; Ayer et al., 1993),
the oncomiR-138 facilitates formation of a stable MYC-
MAX complex and may indirectly enhance oncogenic activity
of MYC.
Not surprisingly, targeting tumor suppressors, inhibitors of
proliferation, and transcriptional repressors, miR-138 indirectly
activates several genes involved in tumorigenesis. This is
confirmed by the downregulation of Cyclin D1 (CCND1), Cyclin
A2 (CCNA2), Aurora kinase A (AURKA), and proto-oncogene
c-Myc (cMYC) on miR-138 inhibition (Figure 5A). Concomitant
repression of these genes using gene-specific shRNAs results
in a decrease in S phase population coupled with an increase
in sub-G1 population, suggesting that targeting these genes
partially phenocopy the effect of antimiR-138 in GSCs (Fig-
ure S3A). In conclusion, targeting specific inhibitors of prolifera-
tion, miR-138 indirectly modulates the expression of several
genes to promote proliferation, underscoring its role as an
oncomiR.
Finally, to examine whether the oncomiR-138 alone can
confer a transformed phenotype, we transduced normal NSCs
(Lonza) with lentivirus expressing miR-138. Ectopic expression
of miR-138 in NSCs results in a moderate increase in size of neu-
rospheres formed when compared with the scrambled control
(Figure S3B). Time course gene expression analysis by quantita-
tive stem-loop real-time reverse-transcription PCR further
confirmed that overexpression of miR-138 in NSCs results in
a significant downregulation of a few targets accompanied by
a moderate increased expression of a few genes influenced indi-
rectly by miR-138 (Figure S3C). These results highlight that
miRNA expression is highly context specific, and ectopic
expression of miR-138 alone may not transform normal NSCs
to GSCs.CelmiR-138 Is a Potential Prognostic Biomarker
Elevated expression of miR-138 in secondary GBMs compared
to the primary GBMs (D’Urso et al., 2012) (GSE13030) (Fig-
ure 6B) and expression in GSCs prompted us to study the ex-
pression of miR-138 in tumor recurrence. Increased miR-138
expression in tumor sections from patients with recurrent
GBM compared to patients with first diagnosis and control
normal human brain sections suggests a role of miR-138 in
tumor recurrence (Figures 7A–7C). To determine the clinical
significance of miR-138 expression, we used data-driven
grouping (DDg) method to classify patients into high-risk and
low-risk groups, based on an optimal expression cutoff that
provides the best separation of their survival curves. We
focused on subgroups of patients with tumor progression or
recurrence. In TCGA analysis of 197 GBM patients with tumor
progression, we found a potentially oncogenic pattern for
miR-138 (p = 0.129; Figure 7D). On the other hand, for the group
of 80 patients with tumor recurrence, DDg method can provide
significant separation of patients into two risk groups based on
miR-138 expression (p < 0.05; Figure 7E). This suggests a poten-
tially oncogenic role of miR-138 in tumor recurrence, which
leads to higher risk of mortality.
As a negative control, we investigated miR-21 to stratify
patients into high- and low-risk groups based on tumor recur-
rence using Mann-Whitney U test. GBMs display high levels of
miR-21 (Chan et al., 2005; Corsten et al., 2007; Papagiannako-
poulos et al., 2008). Results show that miR-21 is not differentially
expressed in these groups (p = 0.736), suggesting that miR-21’s
expression is unlikely to contribute to grouping of patients ac-
cording to their risk. Together, this highlights the clinical signifi-
cance of miR-138 as a potential prognostic biomarker and its
association with tumor recurrence and survival.
DISCUSSION
The discovery of GSCs, highly tumorigenic, self-renewing
subpopulation of GBM cells, suggests that therapeutic
approaches to effectively eradicate these cells may improve
patient outcome. We report the identification of oncomiR-138
as amolecular signature of GSCs. TargetingmiR-138 expression
with antimiRs significantly impaired the growth and survival of
GSCs.l Reports 2, 591–602, September 27, 2012 ª2012 The Authors 597
Figure 7. miR-138 Is a Potential Prognostic
Biomarker
(A) ISH with miR-138 probe or scramble probe on
patient-derived GBM tumor sections and control
non-neoplastic normal human brain sections (n =
12). Note increased staining with miR-138 probe in
patients with recurrent GBM compared to patients
with first-diagnosis GBM. The normal brain tissue
exhibits little or no staining. Scale bar, 100 mm.
(B) Quantification of miR-138 expression in
patients with first diagnosis compared to patients
with tumor recurrence normalized to nuclear DAPI
staining (*p < 0.05).
(C) Quantification of miR-138 transcript abun-
dance by quantitative stem-loop real-time
reverse-transcription PCR in patients with first
diagnosis compared to patients with tumor
recurrence (*p < 0.05).
(D) Kaplan-Meier survival curves representing the
classification of 197 patients with tumor progres-
sion by DDg method (p = 0.129).
(E) Kaplan-Meier survival curves representing 80
patients with tumor recurrence (p < 0.05). Black
and red curves denote patients with low and high
miR-138 expression, respectively.The aberrant expression of an oncomiR can repress the
expression of its target tumor suppressor genes resulting in
oncogenesis. GSCs express elevated levels of miR-138 not
miR-21, and knockdown of miR-138 has a deleterious effect
on GSCs. Apparently, for GSCs, miR-138 is a prosurvival onco-
miR, and miR-138-mediated altered protein synthesis may
promote cellular transformation. MYC, indirectly activated by
miR-138, is known to trigger an antiapoptotic signaling cascade
in GSCs (Wang et al., 2008; Zheng et al., 2008). The oncogenic
activity of MYC requires dimerization with MAX. Targeting
MXD1 (MAD) that competes with MYC for binding to MAX, the
oncomiR-138 facilitates formation of a stable MYC-MAX
complex and indirectly enhances oncogenic activity of MYC.
We therefore hypothesize that targeting tumor suppressors like
MAD, miR-138 facilitates proliferation of GSCs.
A role for miR-138 in evasion of apoptosis is strengthened by
validating the proapoptotic gene, CASP3, as its direct target. Mi-
croarray profiling of antimiR-138-treated cells showed a wide
range of alterations including many predicted target genes. This
includes tumor suppressor candidate 2 (TUSC2), which induces
apoptosis by initiating G1 cell-cycle arrest (Kondo et al., 2001),
andB cell translocation gene 2 (BTG2), an antiproliferative protein598 Cell Reports 2, 591–602, September 27, 2012 ª2012 The Authors(Rouault et al., 1996; Yao et al., 2007). In
addition the master regulator miR-138
may modulate the expression of down-
stream effectors of the p53-driven
signaling pathway that includes BTG2,
and growth arrest and DNA damage-
inducible a (GADD45a). Furthermore,
directly targeting and downregulating
BLCAP, a stimulator of apoptosis and an
inhibitor of the antiapoptotic oncogene Bcell CLL/lymphoma 2 (BCL2), miR-138 may impede apoptosis
by a p53 and NFkB-independent pathway (Fan et al., 2011; Yao
et al., 2007). The oncomiR-138-mediated inhibition of proapopto-
ticgenesandmultiple tumorsuppressorpathwayssimultaneously
may facilitate GSCs to overcome programmed apoptotic cell
death (Figure 6A).
miRNA-138 may modulate cell proliferation pathways through
indirect interaction with critical cell-cycle regulators. Targeting
inhibitors of proliferation like Retinoic acid receptor-a (RARA)
that blocks CCND1 (Ball et al., 1997; Wang et al., 2010) and
metastasis suppressors like Thioredoxin-interacting protein
(TXNIP), a transcriptional repressor of Cyclin A2 (Han et al.,
2003), miR-138 promotes cell proliferation. The oncomiR-138
indirectly enhances aurora kinase activity, a regulator of Cyclin
B1, by targeting GADD45a (Shao et al., 2006). This leads to the
hypothesis that by blocking antiproliferative signals, miR-138
may indirectly control cell proliferation and alter cellular homeo-
stasis in GSCs.
As potent regulators of transcript stability, miRNAs directly
regulate the cell’s proteome and in this process determine
its phenotype and plasticity. miR-138 targets and downregulates
negative regulators of gliomagenesis, such as Ephrin-A1
(EFNA1), that exerts an antioncogenic effect in tumor cells (Liu
et al., 2007), and Pannexin2 (PANX2), a brain-specific gap-
junction protein with tumor suppressor function. Ectopic ex-
pression of gap-junction proteins in tumor cells is known to
reverse the neoplastic phenotype (Lai et al., 2009). Controlling
transcript stability of these targets, miR-138 potentially facili-
tates gliomagenesis.
GSCs support nonstem tumor cells through a paracrine effect
by inducing neovascularization and play a critical role in tumor
growth (Bao et al., 2006b). The oncomiR-138 may promote
tumor vascularization by targeting Collagen type IV a 1
(COL4A1), an efficient inhibitor of tumor angiogenesis and
neovascularization (Colorado et al., 2000; Nyberg et al., 2008).
It is evident by the loss-of-function phenotype that a strikingly
large number of genes are regulated by miR-138 either directly
or indirectly, and the prosurvival oncomiR potentially plays a vital
role in tumor invasion by coordinating some of the intricate gene
expression programs.
The pattern of a miRNA expression can reflect tumor origin,
stage, and other pathological variables (Lu et al., 2005), and
miRNA can serve as a biomarker. Specific miRNA signatures
can contribute to the phenotypic diversity of glioblastoma
subclasses and predict survival in glioblastoma (Kim et al.,
2011; Malzkorn et al., 2010). miR-138 was found to be differen-
tially expressed in tumors from patients with good prognosis
versus patients with poor prognosis. High-expression miRNA-
138 was associated with poor prognosis for survival, highlighting




GSCs from samples from five patients with malignant glioma (NNI-1, NNI-4,
NNI-8, NNI-11, andNNI-12; obtained after institutional review board-approved
protocol) were cultured as described by Chong et al. (2009), Foong et al.
(2011), and Ng et al. (2012). Cells were cultured in chemically defined
serum-free selection growth medium with 20 ng/ml basic fibroblast growth
factor (bFGF), 20 ng/ml epidermal growth factor (EGF), 20 ng/ml human re-
combinant leukemia inhibitory factor (LIF), 5 mg/ml heparin, serum-free
supplement (B27) in a 3:1 mix of Dulbecco’s modified Eagle’s medium
(DMEM) and Ham’s F-12 Nutrient Mixture (F12). Cultures were incubated
at 37C and 5% CO2, with growth factor replenishment. Neurosphere
cultures were expanded by mechanical trituration. Normal human NSCs/
progenitor cells were obtained from Lonza. In addition, NSCs were also
obtained from subventricular zone (SVZ) and the frontal lobe (FL) of the
cortex of human brain (Kobayashi et al., 2010). NSCs were cultured as free-
floating neurospheres in a serum-free DMEM/F12 medium (Invitrogen)
supplemented with bFGF (20 ng/ml; PeproTech), endothelial growth factor
(EGF, 10 ng/ml; PeproTech), 2 mg/ml heparin (Sigma-Aldrich), and 2% B27
(Invitrogen).
Immunocytochemistry on Differentiated GSCs
GSCs (NNI-1, NNI-4, and NNI-8 [passage #36–40]) on coverslips coated with
Laminin and poly-L-ornithine (Sigma-Aldrich) were grown in differentiation
medium. Cells were fixed in 4% PFA, and incubated overnight with the
following primary antibodies: anti-GFAP (Sigma-Aldrich), anti-b-Tubulin
(Covance), anti-O4 (Millipore). After washing, cells were incubated with
secondary antibodies: anti-mouse Alexa 568, anti-rabbit Alexa 488, or anti-
mouse Alexa 488 IgM from Invitrogen at room temperature. Nuclei were
counterstained with DAPI. Image acquisition was done with Olympus
FV1000 confocal microscope.CelTumorsphere-Formation Assay
Harvested spheres (NNI-8, passage #36) were dissociated and plated as
single cells in 96-well plates by serial dilution or FACS. The number of wells
with tumorspheres was scored after 21 days.
miRNA Profiling
Total RNA from GSCs (NNI-8, passage 34) and NSCs (Lonza, passage 3)
was subjected to miRCURY LNA Array microRNA profiling (Exiqon). After
background subtraction and normalization, differential gene expression anal-
ysis was performed. A multiple ANOVA model was used to remove batch
effects from replicate samples.
Microarray Analysis for Determination of Gene Expression Profile
Total RNA (500 ng) from three replicates of GSCs (NNI-8, passage 34) trans-
duced with antimiR-138 or scrambled control was converted to biotinylated
cRNA using TargetAmp Nano-g Biotin-aRNA labeling kit (Epicenter) and iso-
lated using QIAGEN columns. cRNA was hybridized on HumanWG-6 v3.0
array (Illumina). Normalized data were analyzed with Illumina BeadStudio,
and analysis was performed on PARTEK platform.
Quantitative RT-PCR
RNA was isolated from GSC lines (NNI-1, NNI-4, NNI-8, NNI-11, and NNI-12
[passage #35–40]) and from NSC lines (fetal whole-brain-derived Lonza, SVZ
derived, and FL derived [passage #3–6]). cDNA was synthesized using miRNA
RT assay (TaqMan), and expression levels of miRNA were analyzed using the
7900 fast RT-PCR system (Applied biosystems) using miR-138-specific
primers. U6 probe was used as an endogenous control. DDCt was used to
determine the transcript abundance.
miRNA Northern Blot Analysis
Northern blot analysis was carried out using 15 mg of small RNA-enriched total
RNA fromGSCs (NNI-8, passage #36). RNAwas separated on 15%denaturat-
ing Urea-PAGE, transferred to nylon membrane (Ambion), and UV crosslinked
(Stratagene). LNA probes for miR-138 and U6 (Exiqon) were end labeled with
T4 polynucleotide kinase. Following hybridization and washing the blot was
processed.
Preparation of Lentiviral Stocks and Transduction
Stable expression of antimiRs was carried out using miRZip, a lentiviral
expression vector (System Biosciences). Mature functional antimiR-138
sequence is CGGCCTGATTCACAACACCAGCT. The H1 expression cassette
provides constitutive RNA polymerase III-dependent transcription of antimiR
transcripts. CMV promoter supports expression of copGFP (fluorescent
reporter) and puromycin-N-acetyl transferase (drug-selectable marker) for
detection and selection of transduced cells, respectively. Lentivirus express-
ing luciferase under human PGK promoter (Campeau et al., 2009) was
obtained from Addgene. Third-generation lentiviruses were produced in
Lenti-X 293T (Clontech) with packaging mix consisting of three constructs,
pMDLg/pRRE, pRSV-Rev, and pMD2.G, from Addgene. Supercoiled DNA
constructs were prepared using QIAGEN maxi preps.
Soft Agar Assay
Single-cell suspension of 2 3 103 cells (NNI-1, NNI-4, and NNI-8; passage
#35–42) was plated in medium containing 0.3% noble agar (Difco) seeded
in 6-well plates containing 1% noble agar. Cells were cultured for 2–
3 weeks with growth factor supplementation. Lentiviral-transduced cells
were subjected to puromycin selection. Cells were incubated with 1 mg/ml
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich),
and colonies were counted using MATLAB software.
Cell-Viability Assay
Lentivirus-transduced GSCs (NNI-1, NNI-4, and NNI-8; passage #35–42) were
plated at a density of 5,000 cells/well for growth curve analysis. Live cells were
determined at the indicated number of days after plating using the Cell
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Caspase-3/7 Assay
Lentivirus-transduced GSCs (NNI-1, NNI-4, and NNI-8; passage #35–42) were
plated at a density of 5,000 cells/well, and Caspase-3/7 activity wasmeasured
by Caspase-Glo 3/7 Assay (Promega). Relative units were normalized to the
number of viable cells.
Cell-Cycle Analysis
Lentivirus-transduced GSCs (NNI-8, passage #38) were plated at a density
of 100,000 cells/well, labeled with 10 mM EdU for 5 hr prior to harvesting,
and processed using the Click-iT EdU Alexa Fluor 647 Flow Cytometry assay
(Invitrogen), and cell nuclei were counterstained with 25 mg/ml propidium
iodide (Sigma-Aldrich). Samples were subject to EdU incorporation analysis
on a BD FACS caliber (Becton Dickinson). Data were analyzed using WIN-
MDI 2.9 software.
TUNEL Assay
Lentiviral-transduced GSCs (NNI-8, passage #38) cultured for indicated time
points were fixed, and paraffin-embedded sections were subjected to Dead-
End fluorometric TUNEL assay (Promega). Cell nuclei were counterstained
with DAPI.
Western Blotting
Cell lysate (NNI-8; passage #38) was resolved by SDS-PAGE and transferred
to PVDF membranes (Millipore). For immunoblots, primary antibodies used
were anti-PARP, anti-LASP1, anti-BTG2, anti-OLIG1 from Abcam or anti-
GADD45a, anti-EFNA1, anti-CCND1, anti-PANX2, anti-TXNIP from Santa
Cruz Biotechnology or anti-AURKA (Cell Signaling), and anti-phospho-
Histone3 (Millipore). Secondary antibodies used were anti-rabbit HRP (Santa
Cruz Biotechnology) and anti-mouse HRP (Jackson Laboratory). All blots
were stripped and reprobed with b-actin antibodies as loading control.
Luciferase Assay
Wild-type 30 UTR reporter constructs of BLCAP, CASP3, and MXD1
constructs (GeneCopoeia) were cotransfected with pCDH-miR-138 or nega-
tive control vector into HEK293T cells using Effectene (QIAGEN). Firefly and
Renilla luciferase activities were measured 24 hr post-transfection using
Dual-Luciferase Reporter System (Promega). The firefly luminescence was
normalized to Renilla luminescence as an internal control for transfection
efficiency. For mutated constructs, miR-138 binding site was mutated using
the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). miR-138
binding site accagc was substituted with cttgat, gaagta, and gcagaa in
BLCAP, MXD1, and CASP3, respectively.
miR-138 ISH
Five micron sections were processed and boiled in pretreatment solution
(Panomics), washed in PBS, followed by protease (Panomics) treatment
37C. Sections were incubated with LNA probes (50 DIG-labeled LNA probes
specific for miR-138 or scrambled probe with no homology to known verte-
brate miRNAs [Exiqon]) in hybridization buffer (Roche) at 51C for 4 hr.
Sections were blocked with 10% goat serum and incubated with anti-DIG
alkaline phosphatase (Roche). miRNA bound LNA probes were detected by
Fast Red Substrate (Panomics). After counterstaining with DAPI, slides were
mounted using FluorSave (Merck). Image acquisition was performed with
Olympus FluoView FV1000 using TRITC filter.
Intracranial Implantation of GSCs
Intracranial transplantation of GSCs (NNI-8, passage # 40–45) into 8-week-old
NOD/SCID/IL2rg mice (Jackson Laboratory) was performed in accordance
with the Institutional Animal Care and Use Committee-approved protocol.
Luciferase-expressing GSCs bearing either antimiR-138 or scramble control
were orthotopically transplanted following washing and resuspension in
PBS. A total of 153 104 cells in 3 ml was injected stereotactically into the fore-
brain of immunodeficient mice and maintained till the development of neuro-
logical symptoms. Brain collected from the euthanized mice was fixed in 4%
PFA, embedded and sectioned, and subjected to H&E.600 Cell Reports 2, 591–602, September 27, 2012 ª2012 The AuthorGSC Luciferase Preparation and Bioluminescence Imaging
GSC luciferase stables (NNI-8; passage #40–45) were established by selecting
for puromycin (1 mg/ml) after transducing with lentivirus expressing luciferase
under human PGK promoter (Addgene). For bioluminescence imaging, GSCs
bearing scramble control or antimiR-138 and expressing firefly luciferase were
injected into the right forebrains of NOD-SCID mice, and Xenogen system was
used for imaging. After an intraperitoneal dose of 150 mg/kg of D-luciferin,
mice were anesthetized, and imaging was performed using IVIS Spectrum
Imaging System (Xenogen). Quantification was based on total flux (photons/
s) of emitted light as a measure of the relative number of viable cells. Biolumi-
nescence signals were analyzed using Living Image software (IVIS Living
Image v3.0).
Data Preprocessing of miRNA Expression Profiling
miRNA microarray expression data from 494 samples were downloaded from
TCGAGBM database. Outlier removal and batch effect correction procedures
were performed. Quality assessment to identify poor-quality chips was done
by utilizing several visualization methods and statistical indicators on Agilent
Total Gene Signal. The statistical indicators were the median of log2 intensity,
log intensity ratio M, relative log expression (RLE), and correlation among
samples. Samples that fail in more than two indicators were identified as
outliers and subsequently removed. Invariant set normalization (ISN) was per-
formed to normalize the data. Nonparametric Combat software (Johnson et al.,
2007) that applies an empirical Bayes approach was utilized to correct batch
effect. A total of 57 miRNA data sets as outliers were removed from analysis.
Survival analysis was performed using Cox proportional hazard regression
model and DDg method. Clinical information for 596 patients, each containing
data such as time to last follow-up/progression/recurrence, vital status, and
types of treatments received, is downloaded. Data-driven survival analysis is
a published method of assigning patients to distinct groups according to their
risk for death (Motakis et al., 2009). For each gene of interest, the method esti-
mates the expression cutoff of the gene expression by maximizing the separa-
tion of the survival curves associated with the low- and high-risk patients.
Statistical Analysis
Values are reported as the mean ± SE. Statistical significance between two
samples was determined with two-tailed Student’s t test using GraphPad.
Human Brain Tissue
Human brain tumor and control tissue specimens were obtained from the
Medical University of Graz. Biopsy specimens were registered in the respec-
tive biobank and kept anonymous. The research project was authorized by
the ethical commission of the Medical University Graz (EK-number 21-520
ex 09/10). The study protocol was in accordance with the ethical guidelines
of the Helsinki declaration and the Austrian law.
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